> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA OKs Expanded Impella Heart Pump Use
- URL: https://www.fdaweb.com/fda-oks-expanded-impella-heart-pump-use/
- Published: 2019-05-13T12:00:00.000Z
- Updated: 2026-09-15T01:26:19.000Z
- Author: David McFarland
- Tags: Devices, #legacy-id-D5144096

FDA has approved Abiomed’s expanded use of its [Impella 5.0](https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.abiomed.com%2Fimpella%2Fimpella-50&esheet=51983764&newsitemid=20190513005623&lan=en-US&anchor=Impella+5.0&index=1&md5=e29e1a2a6ac48b505638fb4753ad07ac&ref=fdaweb.com) and [Impella LD](https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.abiomed.com%2Fimpella%2Fimpella-50&esheet=51983764&newsitemid=20190513005623&lan=en-US&anchor=Impella+LD&index=2&md5=74ee7c4052931222a6f5b7d67c1f3549&ref=fdaweb.com) heart pumps for treating cardiogenic shock. The expansion extends the duration of support for each pump from six days to 14 days. The forward flow heart pumps are intended for stabilizing a patient’s hemodynamics, unloading the left ventricle, and perfusing the end organs, allowing for the potential of native heart recovery or return to heart function baseline, the company says. The Impella 5.0 is implanted through the femoral or axillary artery and the Impella LD is implanted directly into the aorta. Both allow patients to walk around the unit while on support.